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Plasmacytoid DCs (pDCs) are innate immune cells that are specialized to produce IFN-a
and to activate adaptive immune responses. Although IFN-a inhibits HIV-1 replication in
vitro, the production of IFN-a by HIV-activated pDCs in vivo may contribute more to HIV
pathogenesis than to protection. We have now shown that HIV-stimulated human pDCs
allow for persistent IFN-a production upon repeated stimulation, express low levels of
maturation molecules, and stimulate weak T cell responses. Persistent IFN-a production by
HIV-stimulated pDCs correlated with increased levels of IRF7 and was dependent upon the
autocrine IFN-a/b receptor feedback loop. Because it has been shown that early endosomal
trafficking of TLR9 agonists causes strong activation of the IFN-a pathway but weak
activation of the NF-kB pathway, we sought to investigate whether early endosomal
trafficking of HIV, a TLR7 agonist, leads to the IFN-a–producing phenotype we observed.
We demonstrated that HIV preferentially traffics to the early endosome in human pDCs and
therefore skews pDCs toward a partially matured, persistently IFN-a–secreting phenotype.
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Plasmacytoid DCs (pDCs) are innate immune cells that circulate in 
the blood and lymphoid tissues and are specialized to produce copi-
ous amounts of type I IFNs (IFN-α/β) in response to stimulation 
by virus-associated single-stranded RNA and unmethylated CpG 
DNA through the engagement of TLR7 and TLR9 within the endo-
somal compartment (1–3). HIV recognition by pDCs is mediated by 
the innate receptor TLR7 and requires its endocytosis followed by 
endosomal acidification (1). IFN-α inhibits HIV-1 (HIV) replication 
in vitro, but pDCs are now implicated in vivo in promoting both 
mucosal infection and chronic immune activation (4–7).
pDCs are the earliest cells to arrive to the mucosal site of SIV 
inoculation, and their production of cytokines recruits and acti-
vates CD4+ T cells for infection (4). HIV infection is marked by 
aberrant immune activation, which correlates more with disease 
progression than with viremia (8–13). The cause of immune activa-
tion in AIDS is unknown, but stimulation of innate immune cells 
directly by HIV and indirectly by products of bacterial transloca-
tion may be major contributors. Both human and animal studies 
support a role for IFN-α in HIV pathogenesis. High plasma titers 
of IFN-α during acute and late-stage disease have been shown to 
correlate with disease progression (5). Women progress to AIDS 
more rapidly than men, express higher markers of immune activa-
tion, and produce more IFN-α per pDC when challenged with HIV 
ex vivo (14). Lymphoid tissue and circulating PBMCs derived from 
HIV-infected subjects with progressive disease express much high-
er levels of IFN-α and related inducible genes compared with unin-
fected controls (6, 7). Transcriptional profiling in pathogenic and 
nonpathogenic SIV-infected primates reveal differences in IFN-α 
responses: both hosts have strong IFN-α response signatures dur-
ing acute infection, but only the pathogenically infected animals 
that go on to develop AIDS maintain elevated IFN-α response sig-
natures over the course of chronic infection (15–18). Classically, 
pDCs are described as being refractory to IFN-α production upon 
repeated stimulation with synthetic TLR7 or TLR9 agonists, which 
is thought to be a protective mechanism against excessive immune 
activation (19, 20). To our knowledge, pDC tolerance to repeated 
stimulation with HIV, a TLR7 agonist, has never been evaluated, 
but we and others have observed that pDCs from HIV-infected sub-
jects can be stimulated ex vivo with HIV to produce IFN-α (21, 22). 
Because pDCs derived from HIV-infected subjects have been 
exposed to HIV in vivo, we reasoned that HIV may uniquely allow 
for repeated stimulation of pDCs.
The studies presented here demonstrate that HIV-activated 
human pDCs were incompletely matured upon activation and 
were not refractory to repeated stimulation to produce IFN-α. 
In comparison, R848 (Resiquimod), a synthetic TLR7/8 ligand; 
type B CPG oligodeoxyribonucleotide (CpGB), a synthetic TLR 9 
ligand; and heat-inactivated influenza virus and Sendai virus, 2 
other viruses thought to activate pDCs through TLR7; matured 
pDCs more fully and rendered the cells either totally or partially 
refractory to further stimulation to produce IFN-α. We provide 
evidence for a mechanism whereby HIV traffics predominantly to 
early endosomes rather than late endosomes, favoring persistent 
IFN-α production over maturation. Persistent bioactive IFN-α 
production by HIV-stimulated pDCs correlated with increased 
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Figure 1
HIV-activated pDCs are not refractory to restimulation to produce IFN-α. (A and B) pDCs were incubated with media alone (0), AT-2 HIV (AT2), 
live HIV (LMN), R848, influenza virus (Flu), Sendai virus, CpGA, or CpGB for 18 hours. Supernatants were removed, and cells were washed, 
counted, and restimulated for 18 hours (restimulation denoted as 0-0, AT2-AT2, LMN-LMN, etc.). IFN-α was (A) measured in the supernatants 
by ELISA and (B) corrected for cell number. (C) Experiments were repeated for 6–10 donors. Percent IFN-α restimulation denotes IFN-α pro-
duced after the second stimulation relative to that after the first. Dots represent mean of 2 replicates per donor. (D) HIV-stimulated pDCs could 
be restimulated with different TLR ligands, whereas R848-stimulated pDCs could not be restimulated. Data are means (n = 2 replicates) and 
representative of 2 independent experiments. (E) pDCs were stimulated with media or AT-2 HIV for 12 hours; sorted; separated into IFN-α– 
secreting and non–IFN-α–secreting cells; and then stimulated with AT-2 HIV for 24 hours. AT-2 HIV–activated IFN-α–secreting pDCs produced 
more cytokine per cell than did HIV-activated pDCs that did not produce IFN-α upon initial stimulation. Data are means (n = 2 replicates) and 
representative of 2 independent experiments. (F) Culture supernatants were applied to a COS1 pRLpISRE cell line that produces luciferase 
upon exposure to bioactive type I IFNs. pDCs produced bioactive type I IFN upon repeated stimulation with HIV. Data are mean ± SEM (n = 2 
replicates) and representative of 3 independent experiments.
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levels of the transcription factor IRF7 and was dependent upon 
the autocrine IFN-α/β receptor feedback loop. By skewing pDCs 
toward a partially matured and persistently IFN-α–secreting 
phenotype, HIV may promote its survival by blunting adaptive 
immune responses and by inciting inflammatory responses to 
amplify activated target cells for infection.
Results
HIV-activated pDCs are not refractory to restimulation to produce IFN-α. 
We first evaluated whether pDCs can be restimulated by HIV to 
produce IFN-α after incubation with HIV compared with other 
TLR7 and TLR9 agonists. Purified pDCs were incubated with live 
HIV, 2,2′ dithiodipyridine–inactivated HIV-1 (AT-2 HIV), R848, 
heat-inactivated influenza virus, Sendai virus, CpGA, or CpGB for 
18 hours. Culture supernatants were removed after centrifugation, 
and cells were washed, counted, 
resuspended in culture media, and 
restimulated for another 18 hours. 
IFN-α was measured in these cul-
ture supernatants by ELISA and 
corrected for cell number (Figure 1, 
A and B). Cell numbers for the rep-
resentative experiment shown in 
Figure 1, A and B, and ranges for all 
experiments are shown in Table 1. 
Purified pDCs stimulated with 
live HIV, AT-2 HIV, or CpGA were 
not refractory to restimulation. All 
experiments were performed with 
300 ng/ml of CXCR4 tropic MN 
HIV, as this amount and type of HIV 
lab strain causes maximal IFN-α 
production by pDCs based on prior 
studies (1, 23), but pDCs stimulated 
with CXCR4 MN HIV and CCR5 
tropic ADA HIV at doses ranging 
from 3 ng/ml to 3 μg/ml were also 
not refractory to restimulation (data 
not shown). In comparison, pDCs 
stimulated with R848, CpGB, and 
inactivated influenza were completely refractory to restimulation, 
whereas those stimulated with Sendai virus were partially refrac-
tory (Figure 1C). Furthermore, pDCs first stimulated by R848 were 
refractory to restimulation with both TLR7 and TLR9 ligands and 
pDCs first stimulated by AT-2 HIV were not refractory to restimula-
tion with either TLR7 or TLR9 ligands (Figure 1D). When the length 
of initial stimulation of pDCs was extended to 36 hours, HIV-acti-
vated pDCs still produced IFN-α upon 18-hour restimulation, but 
R848- and CpGB-stimulated pDCs could not be restimulated (Sup-
plemental Figure 1; supplemental material available online with this 
article; doi:10.1172/JCI44960DS1). Of note, R848-stimulated pDCs 
produced a range of IFN-α (0–1 pg/cell) depending on the donor 
tested; however, regardless of the amount of IFN-α produced or 
the amount of R848 used (100 nM to 10 μM), the cells were always 
refractory to further stimulation to produce IFN-α. As demonstrat-
ed in our previous studies, RNAs obtained from control microves-
icles prepared from HIV-uninfected cells matched to those used to 
produce HIV virions are ineffective at activating pDCs (1, 24). To 
confirm that we were restimulating HIV-activated IFN-α–producing 
pDCs and not merely activating pDCs that had not been activated 
during the first overnight incubation, we used the Miltenyi IFN-α 
secretion assay kit to select IFN-α–producing pDCs. pDCs were first 
stimulated with AT-2 HIV for 12 hours, sorted and separated into 
IFN α–secreting and non–IFN-α–secreting cells, and then stimu-
lated again with AT-2 HIV for 24 hours. Instead of becoming refrac-
tory to further stimulation, AT-2 HIV–activated IFN-α–secreting 
pDCs produced even more cytokine per cell than did pDCs that did 
not produce IFN-α upon initial stimulation (Figure 1E). To evalu-
ate whether type I IFNs produced by pDCs upon repeated stimula-
tion with HIV are bioactive, we used a cell-based bioassay using the 
COS1 pRLpISRE cell line that produces luciferase upon exposure to 
bioactive type I IFNs, including all IFN-α subtypes and IFN-β. We 
found that pDCs were able to produce bioactive type I IFNs upon 
repeated stimulation with HIV (Figure 1F). We next investigated 
whether pDCs from HIV-infected subjects retain the capacity to pro-
Table 1




AT-2 HIV 30,000 15,000–35,000
Live HIV 30,000 20,000–30,000
CpGA 25,000 15,000–35,000
R848 45,000 40,000–50,000
Influenza virus 50,000 40,000–50,000
CpGB 45,000 40,000–50,000
Sendai virus 45,000 40,000–50,000
Purified pDCs were initially incubated with the indicated stimuli for 18 
hours; for initial stimulation, all cell counts were 50,000. After removal of 
supernatant, washing, and counting, cells were resuspended in culture 
media and restimulated for another 18 hours with the same stimulus. 
AAbsolute cell number for the representative experiment in Figure 1,  
A and B. BRange for all experiments.
Figure 2
HIV-infected subjects, similar to uninfected donors, produce IFN-α upon restimulation with HIV, but not 
with CpGB, influenza, or R848. (A) pDCs from a chronically HIV-infected subject, incubated with AT-2 
HIV, live HIV, CpGB, influenza virus, or R848 for 18 hours. Culture supernatants were removed after 
centrifugation, and cells were washed, counted, and restimulated for 18 hours. IFN-α was measured in 
the culture supernatants by ELISA and corrected for cell number. (B) Restimulation experiments were 
repeated with AT-2 HIV, CpGB, influenza virus, or R848 for 3 donors, 1 chronically infected (as in A) 
and 2 with early infection. Percent IFN-α restimulation denotes IFN-α produced after second stimulation 
relative to that after the first. Dots represent mean of 2 replicates per donor.
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Figure 3
HIV-activated pDCs, like CpGA-activated pDCs, express lower levels of costimulatory molecules; however, all cells are refractory to inflammatory 
cytokine production upon restimulation, regardless of TLR agonist used. (A) Maturation of pDCs after 18 hours induced by HIV AT-2, live HIV, 
CpGA, CpGB, influenza virus, or R848, as measured by CD86, CD40, and CCR7. Data are from 1 experiment, representative of 5 independent 
experiments. Dashed line is isotype control, dark gray histogram is unstimulated 18 hours, light gray histogram is stimulated with agonist. (B) 
Inflammatory cytokine production by HIV-activated pDCs versus comparator agonists, tested using cytometric bead array analysis. None of 
the agonists, including HIV, allowed for restimulation of inflammatory cytokines compared with initial stimuli (*P < 0.05, Student’s t test). Data 
are mean ± SEM (n = 3 replicates) and representative of 3 independent experiments. (C) Allogeneic T cell proliferation at day 6 after coculture 
with differentially matured pDCs, expressed as percent proliferation by CFSE. pDCs matured with HIV and CpGA stimulated T cell proliferation 
similar to that by unstimulated pDCs, whereas pDCs matured with CpGB, influenza virus, or anti-CD3/anti-CD28 stimulated significantly more T 
cell proliferation than did unstimulated pDCs (*P < 0.05, 2-tailed Student’s t test). Data are represented as mean ± SEM (n = 3 replicates) and 
representative of 4 independent experiments.
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duce IFN-α upon repeated stimulation with HIV. We isolated fresh 
pDCs from HIV-infected subjects and found that pDCs from HIV-
infected subjects, similar to those of uninfected donors, produced 
IFN-α upon restimulation with HIV but not with CpGB, influenza, 
or R848 (Figure 2). All donors were antiretroviral naive; 2 were early-
infected subjects obtained from the NIAID Center for HIV/AIDS 
Vaccine Immunology (CHAVI) cohort with HIV EIA positive, West-
ern blot indeterminate with CD4 346, VL 191,008, and CD4 428, 
VL 434,625, respectively, and the third was a chronically infected 
patient (>5 years) recruited through Bellevue Hospital/NYU with 
CD4 681, VL 59,800.
HIV-activated pDCs express lower levels of costimulatory molecules but 
are refractory to inflammatory cytokine production upon restimulation. 
It is known that pDCs are activated by TLR agonists through the 
engagement between endosomal TLR7 or TLR9 and the adaptor 
molecule MyD88, leading to the assembly of a multiprotein sig-
nal-transducing complex in the cytoplasm that activates and phos-
phorylates IRF7 for initiation of type I IFN gene transcription and 
activates NF-κB and MAPKs to induce the transcription of proin-
flammatory cytokines, chemokines, and costimulatory molecules 
(25). Because the TLR signaling pathways diverge after MyD88 
engagement, we were interested to study whether HIV-activated 
pDCs are unique only in their persistence of IFN-α production, 
or whether there are also differences between HIV and other TLR 
agonists in the NF-κB pathway. pDCs were placed in culture with 
live HIV, AT-2 HIV, R848, CpGA, CpGB, Sendai virus, or heat-inac-
tivated influenza virus. After incubation, cells were washed and 
stained with anti-CD123–PE, anti-CD86–APC, anti-CD40–PerCP, 
anti-CCR7–FITC, or isotype control and analyzed by flow cytom-
etry. HIV-activated and CpGA-activated pDCs upregulated the 
migration molecule CCR7 and costimulatory molecule CD86 to a 
much lesser degree than did pDCs activated with comparator ago-
nists (including Sendai virus; data not shown). CD40 upregulation 
was not different between groups (Figure 3A). To study differences 
between HIV-activated pDCs and pDCs stimulated with the other 
agonists in terms of tolerance to inflammatory cytokine produc-
tion upon restimulation, culture supernatants were tested using 
cytometric bead array analysis. None of the agonists, including HIV, 
allowed for restimulation of inflammatory cytokines (i.e., TNF-α 
and IL-6; Figure 3B). To study whether decreased expression of 
maturation molecules correlates with defective T cell stimulation, 
pDCs were incubated overnight with the various agonists, washed, 
and then cocultured with CFSE-labeled allogenic naive CD4+ or 
CD8+ T cells for 6 days. In concordance with the lower expression 
of costimulatory molecules, pDCs stimulated with HIV and CpGA 
elicited less allogeneic T cell proliferation than did those stimulated 
with CpGB or heat-inactivated influenza (Figure 3C).
HIV-activated pDCs increase mRNA expression of IRF7, which correlates 
with ability to produce secondary IFN-α responses. To understand the 
mechanism by which HIV-activated pDCs do not become toler-
ant to persistent IFN-α production, we first sought to compare 
mRNA expression of TLR7, TLR9, and IRF7 in pDCs exposed to 
either AT-2 HIV or R848. We hypothesized that the maintenance 
or upregulation of these molecules, which are necessary for pDC 
IFN-α signaling, may be responsible for the persistence of IFN-α 
production upon restimulation. As AT-2 HIV is equivalent to live 
HIV in terms of pDC activation through TLR7 (1, 24), we complet-
ed subsequent experiments using AT-2 HIV. Because pDCs are rare 
and cells available for experiments are limited, we focused on com-
paring AT-2 HIV with R848, as R848 is also a TLR7 agonist but 
fully matures pDCs and makes them completely refractory to sec-
ondary IFN-α responses. pDCs were incubated with media alone, 
AT-2 HIV, or R848 for 18 hours and were either washed for imme-
diate preparation of mRNA or washed and placed back in culture 
with AT-2 HIV for 18 hours. TLR7, TLR9, and IRF7 mRNA levels 
were quantified by quantitative real-time RT-PCR (qRT-PCR). 
We found differences in IRF7 expression, but not TLR7 or TLR9 
expression, of pDCs incubated with AT-2 HIV compared with 
R848. Whereas TLR7 expression increased after exposure to either 
AT-2 HIV or R848 compared with unstimulated pDCs, IRF7 
expression increased only in AT-2 HIV–exposed pDCs, decreas-
ing in R848-exposed pDCs. TLR9 expression was variable in pDCs 
exposed to either AT-2 HIV or R848 (Figure 4A). When IRF7 
mRNA expression was measured over 24 hours, unstimulated 
cells spontaneously increased IRF7 expression, and AT-2 stimula-
tion augmented IRF7 expression further, but R848 decreased IRF7 
expression over the time course (Figure 4B). The kinetics of IFN-α 
production were measured using intracellular staining of AT-2 
HIV– or R848-exposed pDCs. R848-stimulated pDCs produced 
IFN-α within 30 minutes but were no longer producing by 2–4 
hours. In contrast, AT-2 HIV–stimulated pDCs did not begin to 
produce IFN-α for 6 hours, but continued to produce at 12 hours 
(Figure 4C). To test whether exogenous IFN-α could rescue the 
block to restimulation with R848, purified pDCs were incubated 
with IFN-α and R848, but again, pDCs could not be restimulat-
ed to produce IFN-α (Figure 4D). Nuclear translocation of IRF7 
after stimulation of HIV versus R848 was also tested. pDCs were 
exposed to R848 or live HIV for 2–4, 6, or 12 hours. IRF7 nuclear 
translocation was apparent at 2–4 hours after R848 stimulation 
(Supplemental Figure 1C) and was unchanged at 6 and 12 hours 
(data not shown). HIV-activated pDCs did not show evidence 
of IRF7 nuclear translocation at 2–4, 6, or 12 hours (data not 
shown). This is likely because a minority of pDCs are infected 
with HIV by 12 hours; therefore, nuclear translocation of IRF7 in 
these few cells is not readily apparent. To select the minority of 
activated pDCs for microscopic analysis, we sorted HIV-activat-
Figure 4
HIV-activated pDCs increase mRNA expression of IRF7, which cor-
relates with ability to produce secondary IFN-α responses. (A) pDCs 
were incubated with media alone, AT-2 HIV, or R848 for 18 hours, then 
washed for immediate preparation of mRNA or washed and placed 
back in culture with AT-2 HIV for 18 hours. cDNA was prepared for 
qRT-PCR. Relative expression of gene products was normalized to 
GAPDH. Whereas TLR7 expression increased in pDCs exposed to 
either AT-2 HIV or R848, and TLR9 expression was variable, IRF7 
expression increased relative to unstimulated pDCs (*P < 0.05; 
Student’s t test) in AT-2 HIV–exposed pDCs, but decreased in R848-
exposed pDCs. Data are mean ± SEM (n = 3 replicates) and rep-
resentative of 3 independent experiments. (B) IRF7 expression was 
spontaneously increased by unstimulated cells and further augmented 
by AT-2 HIV stimulation, but was decreased by R848 over the time 
course. (C) R848-stimulated pDCs produced IFN-α within 30 minutes, 
but were no longer producing by 2–4 hours. In contrast, AT-2 HIV–
stimulated pDCs did not begin to produce IFN-α for 6 hours, but contin-
ued to produce at 12 hours. Data are representative of 5 independent 
experiments. (D) To test whether exogenous IFN-α could rescue the 
block to restimulation with R848, purified pDCs were incubated with 
IFN-α and R848; again, pDCs could not be restimulated to produce 
IFN-α (*P < 0.05 versus first stimulation with R848; Student’s t test). 
Data are mean ± SEM (n = 3 replicates) and representative of 2 inde-
pendent experiments.
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ed IFN-α–producing pDCs from those that were not producing 
IFN-α after 12 hours, using the Miltenyi IFN-α secretion assay 
kit. Using this strategy, we clearly saw IRF7 nuclear translocation 
in HIV-activated IFN-α–producing pDCs compared with those 
that were not producing IFN-α after 12 hours (Supplemental 
Figure 2D). There was no discernible pattern (i.e., increased cyto-
plasmic as well as nuclear IRF7) in HIV-activated compared with 
R848-activated pDCs.
HIV-activated IFN-α production is IFN-α inducible, in contrast to 
R848-activated IFN-α production. To evaluate whether the auto-
crine type I IFN feedback loop is necessary for IFN-α production 
when pDCs are stimulated with AT-2 HIV in comparison to R848 
(26), we preincubated the pDCs for 30 minutes with blocking 
antibodies to IFN-α, IFN-β, and IFN-α/β receptor and then stim-
ulated the cells for 18 hours with AT-2 HIV or R848. IFN block-
ing antibodies attenuated IFN-α production upon AT-2 HIV 
stimulation, but not upon R848 stimulation (Figure 5A), which 
suggests that the IFN-α feedback loop enhances IFN-α secre-
tion upon stimulation with HIV, but not R848. Bioactive IFN-α 
production was confirmed by testing the culture supernatants 
by ELISA for IP-10, an IFN-α–inducible protein (Figure 5B). In 
addition, we noted that IFN blockade reduced IRF7 expression of 
AT-2 HIV–activated pDCs, unstimulated pDCs, and R848-stimu-
lated pDCs (Figure 5C). Our observation that IFN blocking anti-
bodies reduced IRF7 expression 
in unstimulated pDCs was sur-
prising and suggested that pDCs 
use the type I IFN autocrine feed-
back loop to maintain increased 
baseline levels of IRF7.
High baseline mRNA expression of 
IRF7 in unstimulated pDCs is likely 
a result of constitutive low-level type I 
IFN production by pDCs. To test the 
hypothesis that high IRF7 expres-
sion in unstimulated pDCs is not 
constitutive, but is induced by 
spontaneous type I IFN produc-
tion, we used a reporter COS cell 
line that is highly sensitive to type I 
IFNs (lower limit of detection, 
1 U/ml) and produces luciferase 
upon exposure to these cytokines. 
We purified pDCs from 6 different 
donors and incubated the cells for 
18 hours. Culture supernatants 
were applied to the COS cell line 
and assayed for bioactive type I 
IFN. All 6 donors produced vary-
ing amounts of bioactive type I 
IFNs in the absence of stimula-
tion (Figure 6A). To explore this 
phenomenon further, we sorted 
pDCs and myeloid DCs (mDCs) 
to 99% purity and prepared fresh 
cells and incubated cells over-
night in culture media without 
additional stimuli. IFNA and 
IFNB mRNA were expressed at 
low levels in pDCs, but not mDCs, 
although expression did not increase significantly after overnight 
incubation. However, in pDCs, but not mDCs, IRF7 and IFN-stim-
ulated gene 54 (ISG54) increased significantly after overnight incu-
bation (Figure 6, B and C), again suggesting that human pDCs 
express low levels of bioactive type I IFNs that maintain increased 
baseline IRF7 and other IFN-stimulated genes.
SOCS1 and SOCS3 are not inhibited by HIV. The SOCS protein 
family has been implicated in the negative regulation of many 
cytokine-stimulated pathways. SOCS1 and SOC3 are strongly 
induced by IFN-α, and overexpression of these proteins has been 
shown to suppress IFN-α production by interfering with the JAK/
STAT pathway (J.J. Krolewski, unpublished observation). We were 
interested to investigate whether there are differences in SOCS1 
and SOCS3 mRNA expression in pDCs exposed to AT-2 HIV or 
R848. AT-2 HIV caused gradually increased expression of both 
SOCS1 and SOCS3 over 24 hours compared with unstimulated 
pDCs. R848 caused a sharp and immediate increase in SOCS3, but 
not SOCS1, although the increased expression was not sustained 
(Figure 7). Early upregulation of SOCS3 might contribute to inhi-
bition of further IFN-α production after R848 stimulation.
HIV is retained in early endosomes. Studies have suggested that TLR9 
signaling in early endosomes leads to IFN-α production by pDCs, 
whereas TLR9 signaling in late endosomes induces pDC matura-
tion and inflammatory cytokine production (27–29). Because HIV 
Figure 5
HIV-activated IFN-α production is IFN-α inducible, whereas R848-activated IFN-α production is not. 
(A) pDCs were preincubated for 30 minutes with blocking antibodies to IFN-α, IFN-β, and IFN-α/β 
receptor and then stimulated for 18 hours with AT-2 HIV or R848. IFN blocking antibodies attenuated 
IFN-α production upon AT-2 HIV stimulation (*P < 0.05 versus AT-2 HIV stimulation without antibodies; 
2-tailed Student’s t test), but not R848 stimulation. Data are mean ± SEM (n = 3 replicates) and repre-
sentative of 4 independent experiments. (B) Bioactive IFN-α production was confirmed by testing the 
culture supernatants by ELISA for IP-10, an IFN-α–inducible protein. (C) IFN blocking antibodies also 
reduced IRF7 expression of AT-2 HIV–activated pDCs and reduced expression of IRF7 in unstimulated 
and R848-stimulated cells.
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and CpGA similarly stimulate pDCs to produce persistent IFN-α 
responses and express low levels of markers of maturation, we 
sought to investigate whether HIV, like CpGA, also traffics primar-
ily to early endosomes. pDCs were stimulated with fluorescently 
labeled GFP-HIV, FAM-CpGA, or FAM-CpGB. GFP-HIV was gen-
erated using a Vpr mutant of the X4-tropic HIV pNL4-3 and eGFP-
Vpr plasmids; therefore, the viruses are nonreplicative, and the 
GFP protein visualized by microscopy incorporates with the coni-
cal core of the HIV particle, which is thought to be closely associ-
ated with the viral RNA (30, 31). This system has been used to tag 
HIV particles in order to follow intracellular virus behavior during 
the early steps of infection of target cells (32, 33). After overnight 
incubation, the fluorescently labeled agonists stimulated pDCs in 
a manner similar to that of unlabeled agonists (i.e., GFP-HIV), and 
FAM-CpGA stimulated pDCs to produce strong IFN-α responses 
but minimal expression of CD86, whereas FAM-CpGB–stimulated 
pDCs produced minimal IFN-α and induced high expression of 
CD86 (data not shown). For lysotracker imaging, pDCs were incu-
bated with GFP-HIV or CpGA for 18 hours or CpGB for 1 hour. 
These time points were chosen because minimal GFP-HIV or FAM-
CpGA was taken up by pDCs before 12 hours, and FAM-CpGB was 
taken up entirely by 1 hour and was subsequently degraded and no 
longer visualized at 12 hours (data not shown). After incubation, 
pDCs were imaged live for analysis of late endosomal/lysosomal 
(lysotracker) trafficking or fixed and stained with specific anti-
bodies for early endosomal and recycling compartments (EEA-1 
and transferrin receptor). Live lysotracker trafficking and fixed 
cells were imaged using the Advanced Precision PersonalDV imag-
ing system at ×60. Images were deconvoluted and analyzed using 
ImageJ. Colocalization of fluorescently labeled ligands with endo-
somal markers were analyzed quantitatively using intensity corre-
lation analysis (Figure 8). For each cell that contained both green 
Figure 6
High baseline mRNA expression of IRF7 in unstimulated pDCs is likely a result of constitutive low-level type I IFN production by pDCs. (A) pDCs 
from 6 different donors were incubated in media without stimulation for 18 hours. Culture supernatants were applied to the COS cell line and 
assayed for bioactive type I IFN. All 6 donors produced varying amounts of bioactive type I IFNs in the absence of stimulation compared with 
control (CTL) mDCs. Data are mean ± SEM (n = 3 replicates). (B) pDCs and mDCs from 5 different donors were sorted with FACS ARIA to 99% 
purity. mRNA was isolated from fresh cells (0 h) and after overnight incubation in culture media without stimulation (18 h). qRT-PCR analysis 
revealed that IFNA and IFNB mRNA transcripts were expressed at low levels in pDCs but not mDCs, and expression was variable after overnight 
incubation. However, in pDCs but not mDCs, IRF7 and ISG54 increased after overnight incubation. (C) Pooled data for 5 pDC donors. Change 
in relative expression was calculated as the difference between expression levels of fresh and overnight-stimulated cells divided by the overnight 
expression level, and expressed as a percentage. *P < 0.05, 2-tailed Student’s t test. Data are mean ± SEM (n = 5 donors).
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and red points, image contrast was set to minimize bleed-through 
(range, 100–2,500), background was subtracted, and intensity cor-
relation analysis was performed, including product of differences 
from the mean (PDM) — with positive PDM values correlating 
with Pearson and Mander coefficients consistently greater than 
0.7. The distributions of percent colocalization of agonists with 
endosomal markers were not normal and varied among donors. In 
order to compare characteristics of these divergent distributions 
and to maintain the correlated information within each donor, 
medians and interquartile ranges (IQRs) obtained for each sub-
ject were compared among subjects exposed to HIV, CpGA, and 
CpGB. Nonparametric Kruskal-Wallis tests were used to compare 
the 3 conditions with respect to medians and IQRs. The Wilcoxon 
rank-sum test was then used to compare the combined data for 
HIV and CpGA to CpGB. Table 2 presents the results of analyses of 
pooled pDC microscopy experiments from 2–3 different donors. 
For EEA-1 and transferrin receptor, percent colocalization of HIV, 
CpGA, and CpGB in pDCs differed with respect to intrasubject 
medians and intrasubject IQRs (borderline P ≤ 0.08 in all instanc-
es). HIV- and CpGA-exposed pDCs combined had significantly 
greater percent colocalization with EEA-1 and transferrin recep-
tor, but significantly less with lysotracker, compared with CpGB. 
For lysotraker, results were as above with respect to intrasubject 
medians only, and HIV- and CpGA-stimulated pDCs combined 
had significantly less percent colocalization with lysotracker than 
did CpGB-stimulated pDCs. CpGA and HIV trafficked similarly 
to each other and differently from CpGB for all endosomal mark-
ers studied, and this pattern was statistically significant using the 
Wilcoxon rank-sum test (Figure 9).
Discussion
HIV infection induces an inflammatory and immune-activated 
state characterized by increased levels of plasma inflammatory 
cytokines and increased markers of cell turnover, activation, and 
exhaustion (12, 34–39). Potent antiretroviral therapy restores the 
immune system by suppressing HIV to clinically undetectable lev-
els, but does not completely reverse inflammation and immune 
activation (40). Recent findings reveal that HIV-infected persons, 
even with full virologic suppression on antiretroviral therapy, are 
at increased risk of cardiovascular events and of renal and liver dis-
ease (41). An evolving model suggests that these increased comor-
bidities are linked to heightened inflammation and immune 
activation. The cause of immune activation is unknown, but 
pathogenic stimulation of innate immune cells by HIV is thought 
to be a major contributor (42). For the first time to our knowl-
edge, we have found that pDCs are dysregulated by HIV to per-
sistently produce IFN-α upon restimulation and to incompletely 
mature the cells, which may contribute more to disease pathogen-
esis (inflammation and immune activation) than to protection 
(stimulation of protective adaptive immune responses). Notably, 
previous studies have reported decreased IFN-α production by 
PBMCs from HIV-infected subjects in response to activation by 
TLR agonists ex vivo (22, 43–46), whereas we showed preserved 
and sustained IFN-α responses in response to HIV activation of 
pDCs in vitro. Discrepancies between our results and those of oth-
ers may be based upon differences in TLR agonists used to activate 
pDCs. For example, Anthony et al. evaluated pDC function upon 
stimulation of PBMCs with the synthetic TLR9 agonist CpG (43), 
Chehimi et al. used influenza virus (44), and Kamga et al. used 
herpes simplex virus–1 (45). In our recent study we found that 
pDCs purified from acutely HIV-infected subjects produce nor-
mal to high IFN-α in response to HIV, but low IFN-α in response 
to herpes simplex virus–1, a TLR9-activating virus (21). Moreover, 
it has previously been shown that TLR9- but not TLR7-mediated 
activation of pDCs is inhibited by HIV gp120, further support-
ing the idea that the impairment of pDC function in HIV infec-
tion is specific to the TLR agonist used (47). Although it is likely 
that pDCs exposed to HIV in vivo may respond less well to other 
TLR agonists, especially TLR9 agonists, we have previously shown 
that they are hyperresponsive to HIV ex vivo (21). We now provide 
mechanistic in vitro data in support of this ex vivo observation.
There were striking differences between pDC maturation and 
IFN-α responses to various TLR7 and TLR9 agonists. Whereas 
R848, CpGB, and heat-inactivated influenza virus fully matured 
pDCs and made them refractory to repeated stimulation to pro-
duce IFN-α, Sendai virus was intermediate, and HIV and CpGA 
Figure 7
SOCS1 and SOCS3 are not inhibited by HIV. mRNA expression of IRF7, SOCS1, and SOCS3 in pDCs exposed to AT-2 HIV or R848 is shown. 
Unstimulated pDCs spontaneously increased IRF7 expression; AT-2 HIV stimulation augmented this expression further, but R848 decreased it 
over the time course. AT-2 HIV caused gradual increased expression of both SOCS1 and SOCS3 over 24 hours compared with unstimulated 
pDCs; R848 caused a sharp and immediate increase in SOCS3, but not SOCS1, but the increased expression was not sustained. Data are mean 
± SEM (n = 3 replicates) and representative of 2 independent experiments.
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Figure 8
HIV and CpGA traffic pre-
dominantly to early (EEA-1) 
and recycling (transfer-
rin receptor) endosomes, 
whereas CpGB traffics pre-
dominantly to lysosomes 
(lysotracker). Shown are 
representative images of 
pDCs incubated with GFP-
HIV, FAM-CpGA, or FAM-
CpGB and stained with (A) 
EEA-1 or (B) transferrin 
receptor (Trans) or incu-
bated with (C) lysotracker 
(Lyso). Differential interfer-
ence contrast (DIC), fluo-
rescent, merged, and PDM 
images are shown. Yellow 
in merged and PDM imag-
es indicates colocaliza-
tion; blue/white points in 
PDM images correspond 
to negative intensity corre-
lation (no colocalization). 
Images demonstrating 
colocalization are shown at 
higher magnification in the 
insets. Original magnifica-
tion, ×60; ×120 (insets).
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allowed for persistent IFN-α production upon restimulation. 
There was a delayed onset of IFN-α production by pDCs after HIV 
stimulation, but the production of IFN-α was prolonged, in con-
trast to the effect of R848 stimulation. Moreover, HIV-stimulated 
pDCs maintained high levels of IRF7 mRNA expression, which 
correlated with their ability to produce IFN-α upon repeated 
stimulation. In comparison, R848 fully matured pDCs and down-
regulated expression of IRF7. Microscopy experiments evaluating 
nuclear translocation of IRF7 after HIV versus R848 activation 
did not reveal discernible differences, which suggests that IFN-α– 
producing cells have undergone nuclear translocation of IRF7 
regardless of stimuli. Inhibiting IFN-α signaling using IFN-α/β 
and IFN-α/β receptor blocking antibodies attenuated the ability of 
HIV to stimulate pDCs to produce IFN-α. In fact, blocking IFN-α 
signaling also decreased expression of IRF7 in control nonacti-
vated pDCs in culture media overnight. Using qRT-PCR and a 
reporter cell line–based bioassay, we showed that elevated baseline 
IRF7 mRNA expression in human pDCs is likely not constitutive, 
but rather induced by the spontaneous production of IFN-α/β. To 
our knowledge, this has been demonstrated previously in murine 
pDCs (48), but not conclusively in humans.
Recent studies reveal that pDCs may be functionally dichoto-
mous; depending upon which TLR agonist is used, either they 
produce IFN-α or they develop a mature antigen-presenting phe-
notype capable of stimulating antigen-specific effector memory 
T helper cells (49). Much of the work exploring differences in 
pDC functionality based on distinct TLR ligation has been done 
comparing TLR9 synthetic agonists CpGA and CpGB. It has been 
shown that CpGA-stimulated pDCs cause higher and prolonged 
kinetics of type I IFN production compared with those caused by 
CpGB stimulation. In contrast, CpGB is more active than CpGA 
in stimulating IL-8 production and increasing costimulatory 
and antigen-presenting molecules. Additionally, CpGA, but not 
CpGB, activates the type I IFN receptor–mediated autocrine feed-
back loop (50). Studies using confocal microscopy have shown 
that CpGA forms multimeric complexes and is retained for long 
periods in the endosomal vesicles of pDCs, together with the 
MyD88-IRF7 complex, whereas monomeric CpGB traffics rapid-
ly to late endosomal vesicles (27–29). A recent study showed that 
CpGB and influenza stimulate pDCs to form NF-κB–dependent 
intracellular pools of MHC II molecules that are persistently neo-
synthesized and accumulate in antigen loading compartments. 
In contrast, CpGA stimulation of pDCs does not lead to the for-
mation of MHC II intracellular clusters (51). CpGB-stimulated 
pDCs efficiently process and present CMV antigens and are 
capable of stimulating CMV-specific effector memory T helper 
cells. CpGA-stimulated pDCs produce large amounts of type I 
IFNs, but fail to induce CMV-specific CD4+ effector memory T 
cells to produce IFN-γ (49). Interestingly, influenza virus induces 
IFN-α production but also matures pDCs fully, in comparison 
to CpGB, which stimulates minimal IFN-α production. Ago-
nists such as influenza virus or CpGC can both stimulate IFN-α 
production and antigen-presenting capacity in pDCs; however, 
these pDCs that obtain the mature antigen-presenting pheno-
type cannot be restimulated to produce IFN-α (50). Thus, strong 
maturation correlates with a refractory state to further cytokine 
production. Potential mechanisms for inhibited IFN-α produc-
tion after strong maturation include changes at the transcrip-
tional and posttranscriptional level. At the transcriptional level, 
we showed downregulation of IRF7 mRNA after a strong matu-
rational stimulus (i.e., R848). At the posttranscriptional level, it 
has previously been shown that strong activation of the NF-κB 
signaling pathway causes ubiquitination and proteasomal deg-
radation of IRAK1, a necessary component of the transductional 
transcriptional processor complex necessary for IRF7 phosphor-
ylation and nuclear translocation (52).
In our experiments, we have shown that HIV, like CpGA, partial-
ly matured pDCs and activated the type I IFN receptor–mediated 
autocrine feedback loop, allowing for persistent IFN-α produc-
tion upon repeated stimulation. We found that HIV behaved like 
Figure 9
Statistical analysis of pooled microscopy data. Shown are pooled data from 2–3 different donors per experiment; each symbol represents a cell, and 
different colors represent cells from different donors. Percent colocalization was calculated as PDM-positive green/red intensity correlation points 
relative to green points. Wilcoxon rank-sum tests were used to compare intrasubject medians and IQRs of combined HIV and CpGA subjects with 
those of CpGB-exposed pDCs from different donors. HIV and CpGA had similar trafficking colocalization; both differed significantly from CpGB.
Table 2
Statistical analysis of microscopy data
Marker	 Descriptor	 P	(all)A	 P	(vs.	CpGB)B
EEA-1 Median 0.054 0.02
EEA-1 IQR 0.06 0.02
Lysotracker Median 0.052 0.02
Lysotracker IQR 0.63 0.37
Transferrin receptor Median 0.08 0.03
Transferrin receptor IQR 0.08 0.03
AAll conditions compared; Kruskal-Wallis test. BHIV and CpGA versus 
CpGB; Wilcoxon test.
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CpGA, trafficking to the early endosome to stimulate persistent 
type I IFN responses, instead of to the lysosome, where NF-κB 
and MAPKs are activated to induce the transcription of proin-
flammatory cytokines, chemokines, and costimulatory mol-
ecules and where MHC complexes colocalize for antigen presen-
tation. We speculate that it is the lack of strong activation of the 
NF-κB signaling pathway that allows for restimulation of pDCs 
to produce IFN-α. If CpGA and HIV are being retained in the 
early endosome and therefore not strongly activating the NF-κB 
signaling (maturation) pathway, pDCs can be persistently stimu-
lated to produce IFN-α. Additionally, because IFN-α production 
relies on a positive feedback loop involving IRF7 upregulation, 
retention of activating ligands in the early endosomes may fur-
ther facilitate ongoing IFN-α production. In vivo, HIV may act 
upon pDCs to skew their responses toward an IFN-α–producing 
phenotype while failing to induce efficient HIV antigen presenta-
tion to HIV-specific effector memory T cells. Effective HIV-spe-
cific CD4+ and CD8+ T cells are deficient in chronic HIV infection 
and likely strongly contribute to lack of virologic control (53, 54). 
Little is known regarding the mechanisms by which HIV-stimu-
lated pDC dysregulation may contribute to immune activation 
and poor adaptive immune stimulation. Deeper understanding 
of HIV-pDC interactions and the TLR-induced signaling path-
ways that regulate type I IFN production versus maturation and 
antigen presentation could elucidate new therapies targeting 
immune activation and inflammation in HIV disease.
Methods
Cells. PBMCs were separated on Ficoll-Hypaque (Amersham Biosciences) 
from buffy coats (New York Blood Center). pDCs were purified by BDCA-4 
magnetic bead separation (Miltenyi Biotec) as described previously (1), with a 
purity ranging from 80% to 95%. Cells were cultured in RPMI 1640 Glutamax 
(Invitrogen) with 5% PHS (Innovative Research), gentamicin, and HEPES.
HIV subjects. Subjects were recruited through NYU and CHAVI 012 clini-
cal sites (Aaron Diamond AIDS Research Center, New York, New York, 
USA, and University of North Carolina, Chapel Hill, North Carolina, 
USA) to undergo leukapheresis to allow for collection of large numbers of 
PBMCs. This study was reviewed and approved by the Institutional Review 
Board of Bellevue Hospital, New York University School of Medicine, Uni-
versity of North Carolina Chapel Hill, Aaron Diamond AIDS Research 
Center, and CHAVI. Written informed consent was obtained from all study 
participants in accordance with the Declaration of Helsinki.
Activating agonists. Purified pDCs were stimulated at 50,000 cells/100 μl 
media at 37°C, 5% CO2, with R848 (10 μM; 3M Corp.), CpGB (5′-T*C*G*T
*C*G*T*T*T*T*G*T*C*G*T*T*T*T*G*T*C*G*T*T*-3′, with asterisks 
denoting phosphorothioate bonds; 2 μg; IDT), CpGA (5′-G*G*G*GGACGAT
CGTC*GG*G*G*G*G-3′; 2 μg; IDT), Sendai virus (100 U/ml), and influenza 
virus PR8 heat inactivated at 56°C for 30 minutes in a water bath (MOI 5).
HIV virions. HIV-1MN (X4-tropic) and HIV-1ADA (R5-tropic) were pro-
duced at the AIDS Vaccine Program, National Cancer Institute, as previ-
ously described (1, 23, 24). For preparation of noninfectious virus (AT-2 
HIV) with functionally intact envelope glycoproteins, virus was inactivated 
by treatment with 1 mM AT-2 (Sigma-Aldrich) and purified and concen-
trated as previously described (55). To study markers of maturation, after 
18 hours of incubation, cells were washed and stained with anti-CD123–
PE, anti-CD86–allophycocyanin, anti-CD40–PerCP, anti-CCR7–FITC, or 
isotype control (BD Biosciences — Pharmingen).
Cytokine/chemokine analysis. Supernatants were analyzed using cytometric 
bead array (BD Biosciences — Pharmingen). The presence of IFN-α was 
detected by the multisubtype IFN-α ELISA kit (PBL Biomedical). IP-10 
was detected by ELISA (Invitrogen). For intracellular staining, pDCs were 
incubated at 100,000 cells/200 μl media with either R848 or AT-2 HIV, and 
brefeldin A was added after 30 minutes, 2 hours, 6 hours, or 12 hours; at 
18 hours, cells were washed and stained with PE-conjugated CD123 and 
FITC-conjugated IFN-α in 0.05% saponin.
Allogenic T cell proliferation. pDCs were incubated overnight with media 
alone, AT-2 HIV, CpGA, CpGB, or heat-inactivated influenza; washed; and 
incubated at 1:20 (10,000 pDCs/200,000 T cells) with Miltenyi-bead puri-
fied CFSE-labeled allogeneic CD4+ or CD8+ T cells, as compared with T 
cells alone or T cells with anti-CD3 (1 μg/ml) and anti-CD28 (0.5 μg/ml; 
BD Biosciences — Pharmingen). T cells were isolated from PBMCs using 
negative selection with Miltenyi anti-RO, CD19, CD25, CD14, CD56, and 
then positive selection with anti-CD4 or anti-CD8, purity greater than 90%. 
T cells were incubated with CFSE (1 μM) for 10 minutes and washed and 
counted prior to coculture with pDCs. After 6 days of coculture, CFSE 
dilution was analyzed by FACS.
IFN-α/β blocking. pDCs were incubated (50,000 cells/200 μl) with mouse 
monoclonal antibody against IFN-α, IFN-β, and IFN-α/β receptor chain 
(10 μg/ml; PBL Biomedical) or isotype control anti-mouse IgG1κ for 30 minutes. 
AT-2 or R848 was then added, and cells were placed back in culture for 18 hours. 
Cells were washed and prepared for qRT-PCR, and culture supernatants 
were removed and tested for IFN-α and IP-10 by ELISA.
qRT-PCR. pDC RNA was isolated using the RNAeasy Mini kit (Qiagen) 
and converted to cDNA using the Qiagen SuperScript III RT kit, and 
assays were performed using Platinum SYBR Green qPCR SuperMix-UDG 
(Invitrogen) as per protocol. All primers (Table 3) were purchased from 
Operon except the IRF7 primers, which were purchased from Sigma-
Aldrich. Reactions were conducted using the BioRad icycler IQ5 RT-PCR 
detection system. For experiments evaluating spontaneous production of 
IFN-α by examining IFN-related genes of mDCs and pDCs, DC subsets 
were enriched from buffy coats using blood DC isolation kits (Miltenyi 
Biotec), followed by staining with antibodies recognizing lineage markers 
(CD3, CD14, CD16, CD19, CD20, and CD56), CD11c (all from BD Biosci-
ences — Pharmingen), and CD4 (Invitrogen) before sorting by flow cytom-
etry using BD FACS Aria. Both DC subsets were sorted to 99% purity based 
on the absence of lineage markers and the high expression of CD4, with 
mDCs expressing CD11c and pDCs not expressing CD11c.
Quantitative bioassay for type I IFNs. Supernatants of cell cultures after 
stimulatory conditions were assayed for IFN activities using a recombi-
nant COS-1 cell line, which carries a luciferase reporter containing mul-
tiple repeats of IFN-stimulated response element (ISRE). The reporter cells 
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for luciferase activities, and then translated to IFN activities using a stan-
dard curve generated from a serial dilution of human IFN-α2a.
Microscopy. Nonreplicative GFP-HIV was generated by cloning a Vpr 
mutant of the X4-tropic HIV pNL4-3 and eGFP-Vpr plasmids in E. coli; puri-
fied using a Midi/Maxi kit (Qiagen); and transfected (Mirus TransIT-293) for 
48 hours using HEK 293T cells. Supernatants were collected, cellular debris 
was removed, and virus was concentrated by ultracentrifugation (133,907 g, 
1 hour at 4°C), and quantified using p24 ELISA at 0.23 ng/ml (AIDS Vac-
cine Program). 5′FAM-labeled CpGA and CpGB were purchased from IDT. 
pDCs were stimulated with GFP-HIV (230 pg/ml), FAM-CpGA (1 μg), or 
FAM-CpGB (1 μg). After incubation, cells were washed and added to 0.01% 
poly-l-lysine–coated (Sigma-Aldrich) Lab-Tek chambered no. 1.0 borosilicare 
system wells (Nunc). 30 minutes prior to imaging, lysotracker was added at 
1 μM (Invitrogen). For EEA-1 and transferrin receptor staining, pDCs were 
stimulated with GFP-HIV, FAM-CpGA, or FAM-CpGB; washed; plated on 
0.01% poly-l-lysine–coated culture slides (BD Biosciences — Falcon); fixed 
with 4% paraformaldehyde; permeabilized with 0.1% Triton X-100; blocked 
with 0.5% BSA in PBS; and then stained with mouse anti–transferrin recep-
tor (0.5 μg; Invitrogen) or mouse anti-EEA1 (0.5 μg; BD Biosciences) for 
1 hour. Cells were washed and then stained with goat anti-mouse 568 (5 μg/ml; 
Invitrogen) for 1 hour. Cells were washed, dried, and mounted in Vectashield 
mounting media (Vector Labs). For IRF7 staining, pDCs were stimulated 
with live HIV or R848 for 2–4, 6, and 12 hours; washed; plated on 0.01% 
poly-l-lysine–coated culture slides (BD Biosciences — Falcon); fixed with 4% 
paraformaldehyde; permeabilized with 0.1% Triton X-100; blocked with 0.5% 
BSA in PBS; and then stained with rabbit anti-IRF7 (5 μg/ml; Santa Cruz) 
for 1 hour. Cells were washed and then stained with goat anti-rabbit 488 
(5 μg/ml; Invitrogen) for 1 hour. Cells were washed, dried, and mounted in 
Vectashield mounting media (Vector Labs).
Statistics. Statistical analysis was performed on at least 2–3 independent 
experiments using 2-tailed Student’s t test (Figures 1–7). Statistical analysis 
of microscopy data (Figure 9) used nonparametric Kruskal-Wallis tests and 
the Wilcoxon rank-sum test using SPSS version 16.0 and SAS version 9.2. A 
P value less than 0.05 was considered significant.
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